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Abstract 
Purpose: To explore potential design for pharmacogenomics trials in sepsis, we investigate the interaction between 
pharmacogenomic biomarkers and response to drotrecogin alfa (activated) (DrotAA). This trial was designed to 
validate whether previously identified improved response polymorphisms (IRPs A and B) were associated with an 
improved response to DrotAA in severe sepsis.
Methods: Patients with severe sepsis at high risk of death, who received DrotAA or not, with DNA available were 
included and matched to controls adjusting for age, APACHE II or SAPS II, organ dysfunction, ventilation, medical/
surgical status, infection site, and propensity score (probability that a patient would have received DrotAA given their 
baseline characteristics). Independent genotyping and two‑phase data transfer mitigated bias. The primary analy‑
sis compared the effect of DrotAA in IRP+ and IRP− groups on in‑hospital 28‑day mortality. Secondary endpoints 
included time to death in hospital; intensive care unit (ICU)‑, hospital‑, and ventilator‑free days; and overall DrotAA 
treatment effect on mortality.
Results: Six hundred and ninety‑two patients treated with DrotAA were successfully matched to 1935 patients 
not treated with DrotAA. Genotyping was successful for 639 (DrotAA) and 1684 (nonDrotAA) matched patients. The 
primary hypothesis of a genotype‑by‑treatment interaction (assessed by conditional logistic regression analysis) was 
not significant (P = 0.30 IRP A; P = 0.78 IRP B), and there was no significant genotype by treatment interaction for any 
secondary endpoint.
Conclusions: Neither IRP A nor IRP B predicted differential response to DrotAA on in‑hospital 28‑day mortality.
ClinicalTrials.gov registration NCT01486524
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Background
Pharmacogenomic biomarkers identify patients who have 
altered drug response according to their genotype. For 
example, use of pharmacogenomics of warfarin decreases 
risk of adverse events (severe hemorrhage) and increases 
efficacy [1–3]. Similarly, pharmacogenomics could be 
used to predict how patients with sepsis may respond to 
adjunctive therapies.
Treatment with DrotAA led to variable clinical responses 
in patients with sepsis. Then, one trial conducted in both 
severe sepsis and septic shock found a significant absolute 
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risk reduction (ARR) of 6.1% in the 28-day mortality rate 
[4]. Other trials including only severe sepsis [5] or only 
septic shock [6, 7] failed to find survival benefit. One rea-
son for the highly variable responses to DrotAA treat-
ment observed in clinical trial may be related to genetic 
predisposition. In previous analyses, a combination of 
single nucleotide polymorphisms (SNPs) that defined two 
improve response polymorphisms (IRPs) was associated 
with a significant genotype-by-treatment interaction for 
effect of DrotAA on mortality.
Though DrotAA was withdrawn from the market by Ely 
Lilly, our overarching goal was to elaborate a pharmacog-
enomic approach using DrotAA as a practical example. 
Accordingly, the primary hypothesis was that IRP A and/
or IRP B predict a differential DrotAA treatment effect in 
patients with severe sepsis and high risk of death.
Methods
This is an abbreviated presentation of the methods of the 
current study because the details were published prior to 
undertaking analyses [8].
Prior studies—background on selection 
of pharmacogenomic biomarkers for current study
To screen for genomic biomarkers, a Genome Wide 
Association Study (GWAS) of the PROWESS study [4] 
was performed (unpublished data) using DNA from 1446 
patients to genotype approximately 1.2 million SNPs 
 (Illumina® Human1  M-Duo BeadChip). These results 
were taken forward to an independent cohort of patients 
who had septic shock, some of whom were treated with 
DrotAA and some of whom were not. This small replica-
tion cohort was drawn from St. Paul’s Hospital (SPH) and 
the Vasopressin and Septic Shock Trial (VASST) [9].
The replication cohort was used to confirm two IRPs. 
Two-SNP composite improved response polymorphisms 
(IRPs), A and B, were constructed. Patients were classi-
fied as IRP A+ or  − and IRP B+  or −  if they had one of 
both of the responsive genotype. For each IRP, individual 
patients were considered biomarker positive if they had 
the responsive genotype for either of the SNPs or for 
both of the SNPs in the IRP. The individual SNPs in each 
IRP were associated with a differential DrotAA treatment 
effect in PROWESS (derivation cohort) and replicated in 
the replication cohort (unpublished).
The two SNPs comprising IRP A were chosen based first 
on the alignment of direction and strength of their signals 
by analyzing the interaction of SNP and treatment effect 
on mortality in both the PROWESS study and the replica-
tion cohort. Secondly, these two SNPs were chosen based 
on biological plausibility linking the proteins coded by 
these genes to pathways of sepsis or pathways regarding 
mechanisms of action of DrotAA. The two SNPs of IRP A 
are RYR2 (ryanodine receptor 2 gene) rs684923 on chro-
mosome 1 and ACIN1 (apoptotic chromatin condensa-
tion inducer 1 gene) rs3751501 on chromosome 14. The 
SNP of RYR2 could act to enhance efficacy of activated 
protein C on protection of endothelial permeability via its 
effects on endothelial protein C receptor and sphingosine-
1-phosphate receptor 1 (S1P). When activated protein C 
(APC) binds to PAR1, this triggers more conversion of 
sphingosine to S1P, and this could decrease the amount 
of sphingosine and thus disinhibit the ryanodine receptor. 
We also suggest that this disinhibition of the ryanodine 
receptor by the actions of APC varies according to the 
genotype of the ryanodine receptor.
Phosphorylation of a residue (S422) inACIN1 (Acinus-S 
variant) by AKT (prosurvival kinase) completely inhibits 
cleavage of Acinus-S by caspase-3, abrogating the for-
mation of fragment p17 which is essential for chromatin 
condensation during apoptosis. Apoptosis is increased 
in some tissues and cells (lymphocytes, dendritic cells, 
pulmonary and gut epithelial cells) and is decreased in 
other tissues and cells (neutrophils) in sepsis. This gene 
modulates apoptosis and activated protein C has anti-
apoptotic actions apoptosis so we suggest that there could 
be an interaction between polymorphisms of ACIN1 and 
response to DrotAA. More specifically, the genetic vari-
ants rs3751501 (AA|AG), associated with increased ARR 
(absolute risk reduction) and coding for amino acid 478 
F in ACIN1, would render ACIN1 constitutively non-
phosphorylated at residue 478 F and hence constitutively 
nonphosphorylated at S422, leading to AKT-independent 
regulation of chromatin condensation by Acinus-S during 
apoptosis, because nonphosphorylated acinus-S would be 
constitutively cleavable by caspase-3.
The two SNPs comprising IRP B were chosen based 
solely on the strength of their signals in the PROWESS 
and replication cohorts. These two SNPs are SPATA7 
(spermatogenesis associated 7 gene) rs3179969 on chro-
mosome 14 and FLI1 (Friend leukemia virus integration 
1 gene) rs640098 on chromosome 11.
For the replication cohort, the ARR was 19.7% for IRP 
A +  patients (95% confidence interval (CI) 2.2–37.1%), 
whereas for the IRP A  −   patients the ARR was −8.9% 
(95% CI −22.6–4.9%)(p  =  0.018 unadjusted). The ARR 
was 21.2% for IRP B+  patients (95% CI 3.2–39.2%), 
whereas for the IRP B  −  patients the ARR was −5% (95% 
CI −18.2–8.2%)(p = 0.04 unadjusted).
The current study—overall design
This was an international, multicenter, retrospective, 
controlled, outcome-blinded, genotype-blinded, and 
matched-patients study [8]. Retrospectively accessed 
DNA and clinical data were analyzed to validate the pre-
specified IRPs. Prospective aspects of this study were the 
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genotyping of patients with regard to the IRPs and the 
statistical testing of the prespecified genotype hypoth-
esis. Eight academic centers contributed the data and 
DNA from 10 cohorts (5 EU, 4 US, 1 Canada).
Study population and treatment groups
Patients included in the current study (the INDICATED 
population) met prespecified eligibility criteria [8] and 
DrotAA-treated patients were matched to DrotAA-free 
patients. Eligibility criteria (aligned with the approved use 
of DrotAA in the USA and EU) were used to select the pri-
mary study population (INDICATED). Such patients with 
high risk of death represented common practice for use 
of DrotAA [10–14]. No patient in this study was part of 
a prospective randomized trial of DrotAA. Patients were 
treated according to standard care at their sites, and data 
and DNA samples collected at that time were retrospec-
tively accessed for this study. All patients were enrolled 
after the Food and Drug Administration (FDA) or Euro-
pean Medicines Agency (EMA) approval of DrotAA.
Matching DrotAA‑treated to control patients
The current study incorporated a robust, well-accepted 
matching strategy. A propensity score of the estimated 
probability that a patient would have received DrotAA 
given their key baseline characteristics was calculated, 
and patients were selected as matches had to be within 
a prespecified tolerance on this score. Combining the 
use of propensity scores with covariate matching is supe-
rior to the use of either strategy alone [15]. The intended 
clinical variables for the calculation of the Mahalanobis 
distance and the reasons why these variables were chosen 
were described previously [8].
Syreon Corporation (a clinical research organization) 
conducted the study. A two-phase transfer of data from 
each center was performed to ensure that the selection of 
matched control patients was blinded and unbiased. Data 
transfer 1 included variables to confirm eligibility and to 
conduct the matching. Once the matching was achieved, 
the matched sets of treated and control patients were 
“locked” together. Then data transfer 2 (outcomes and 
genotypic data) was sent to Syreon.
Genotyping
Genotyping for the IRP SNPs was done using a validated 
 Taqman®-based analytical method and the laboratory 
was blinded to treatment and outcome. A 91-SNP ances-
try informative marker (AIM) panel was genotyped by 
the  GoldenGate® analytical method.
Statistical analysis
As previously noted [8], this study had 90% power to 
detect a treatment-by-IRP interaction assuming an 
absolute mortality reduction of 15% in the DrotAA-
treated group compared to control in IRP + patients and 
with 1–2% difference in mortality between the treated 
and control groups in IRP- patients.
The primary analysis was done on the Matched-INDI-
CATED population (comparing the effect of treatment 
in the IRP + and IRP- groups) by testing for the effect of 
the interaction between IRP and DrotAA treatment on 
the primary endpoint in a conditional logistic regression 
model, conditioning on the matching while incorporating 
the principal component scores from the 91-SNP AIM 
panel data (as covariates to control for potential popula-
tion stratification). The primary endpoint was in-hospital 
mortality through Day 28 (i.e., patients were followed 
until hospital discharge or Day 28, whichever came first). 
Each of the primary analyses, one for IRP A and one for 
IRP B, was done as a two-sided test with α = 2.5% for an 
overall, Bonferroni-corrected, type I error rate of 5%.
Results
Prior to matching patients treated with DrotAA dif-
fered significantly from nonDrotAA patients in many 
important baseline clinical respects (Additional file  1: 
Supplement Tables 1–6). After applying the eligibility cri-
teria for the INDICATED population, there were 11,018 
patients not treated with DrotAA from whom to choose 
matched controls for the 738 DrotAA-treated patients 
(ratio 15:1) (Fig.  1). Suitable matches were not available 
for 46 (6.2%) of the 738 INDICATED DrotAA-treated 
patients. Thus, after matching, the number of matched-
INDICATED DrotAA-treated patients was 692. Over-
all the matched ratio was 2.8 control patients for every 
DrotAA-treated patient. Baseline clinical characteristics 
of the matched 692 DrotAA patients were similar to the 
1,935 matched control patients (Table  1). The DrotAA 
group had higher proportion of coagulation dysfunc-
tion and a higher use of vasopressors (Table  1). Match-
ing was done before genotype was known so it is relevant 
to observe that within the IRP A + and IRP A- and the 
IRP B+ and IRP B− genotype subgroups, DrotAA-
treated patients were similar to matched control patients 
(Additional file 1: Supplement Tables 8–19). The Primary 
Analysis Population (PAP) included 639 DrotAA-treated 
patients and 1684 matched controls. The primary rea-
sons why patients could not be included in the PAP were 
insufficient quantity of DNA or unsuccessful genotyping 
(Fig. 1, Additional file 1: Supplement Table 7).
Effect of DrotAA on mortality
Irrespective of genotype, the ARR was in favor of Dro-
tAA (estimated weighted mortality: DrotAA 25.1%, non-
DrotAA 30.5%) (P = 0.006, Additional file 1: Supplement 
Table 21).
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Fig. 1 Patient enrollment in DrotAA and nonDrotAA groups. Superscript notes: 1Based on GoldenGate genotyping for AIM panel SNPs and research 
SNPs. 2Each matched set required 1 DrotAA‑treated patient and 1–3 nonDrotAA‑treated patients
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Primary endpoint: genotype‑by‑DrotAA treatment 
interaction
The primary hypothesis of a genotype by DrotAA treat-
ment interaction assessed by conditional logistic regres-
sion analysis for IRP A was not significant (P  =  0.30, 
Table 2), and the direction of the effect was opposite to 
what had been expected as shown by the negative param-
eter estimate for the interaction term (Additional file  1: 
Supplement Tables 20–21). The IRP B result was also not 
significant (P = 0.78, Table 2), and the direction of effect 
was opposite to what had been expected. There was a 
Table 1 Baseline characteristics for  ALL and  matched-
INDICATED populations by treatment
Baseline 
 characteristicsa
ALL patients Matched‑INDICATED
DrotAA
(n = 784)
NonDrotAA
(n = 18,138)
DrotAA
(n = 692)
NonDrotAA
(n = 1935)
Age (Mean) 58.4 60.4 59.0 59.1
SD 16.1 16.9 15.4 9.2
P  valueb 0.001 0.69
Male (%) 59.7 59.9 60.1 61.2
P value 0.93 0.65
APACHE II (mean) 26.1 21.1 25.8 25.5
SD 8.2 7.7 7.9 4.7
P value < 0.0001 0.02
SAPS II (mean) 58.1 47.8 59.1 58.5
SD 19.2 19.1 18.8 10.9
P value < 0.0001 0.77
Origin of sepsis (%)
Nosocomial 8.4 4.7 7.2 12.3
Community 
acquired
38.6 14.3 39.7 34.7
Unknown 52.9 81.0 53.0 53.0
P value 0.003 < 0.0001
Anatomic site of primary infection (%)
Lung 51.5 23.4 52.9 46.8
Abdomen 12.2 6.9 13.2 12.7
CNS 1.3 0.6 0.9 0.7
Blood 3.4 2.0 3.0 3.5
Urinary tract 4.1 2.7 3.8 3.3
Unknown 22.1 60.2 21.1 29.0
Other 5.4 4.2 5.2 4.1
P value 0.0004 0.55
Use of vasopressors (%)
Yes 91.2 54.7 91.8 81.2
No 8.3 39.2 7.8 17.8
Unknown 0.5 6.1 0.4 1.0
P value < 0.0001 < 0.0001
Mechanical ventilation (%)
Yes 76.3 72.3 75.7 76.4
No 6.4 19.5 6.2 5.2
Unknown 17.3 8.2 18.1 18.4
P value < 0.0001 0.08
Number of organ systems with dysfunction (%)
0 1.4 9.9 0.0 0.0
1 2.2 23.8 0.1 0.8
2 20.7 30.8 21.0 22.0
3 33.0 19.4 35.1 34.0
4 24.9 11.3 26.3 29.4
5 13.6 4.1 13.9 11.7
6 4.2 0.7 3.6 2.2
P value < 0.0001 0.82
Cardiovascular dysfunction (%)
Yes 96.0 66.9 98.7 98.3
a Summary statistics for the NonDrotAA group were weighted to reflect the 
unequal numbers of DrotAA and NonDrotAA patients in each of the matched 
sets
b Descriptive P values are from clustered regression analysis using linear 
regression (numeric variables) or binary logistic regression (categorical variables) 
comparing the proportion of patients in the most frequent category between 
DrotAA vs NonDrotAA, clustering on the matched sets and with weights based 
on the number of patients in DrotAA and NonDrotAA matched sets. Patients in 
the unknown categories were excluded from the tests. No adjustments were 
made to account for multiple inference
Table 1 continued
Baseline 
 characteristicsa
ALL patients Matched‑INDICATED
DrotAA
(n = 784)
NonDrotAA
(n = 18,138)
DrotAA
(n = 692)
NonDrotAA
(n = 1935)
No 2.4 30.2 1.0 1.0
Unknown 1.5 2.9 0.3 0.7
P value < 0.0001 0.36
Pulmonary dysfunction (%)
Yes 92.6 69.5 95.4 95.3
No 5.1 18.8 3.9 3.4
Unknown 2.3 11.7 0.7 1.3
P value < 0.0001 0.34
CNS dysfunction (%)
Yes 28.4 21.0 27.7 31.4
No 33.2 34.5 33.8 30.9
Unknown 38.4 44.5 38.4 37.7
P value 0.0003 0.01
Coagulation dysfunction (%)
Yes 31.4 14.0 31.8 25.0
No 65.4 68.7 66.3 72.6
Unknown 3.2 17.3 1.9 2.4
P value < 0.0001 < 0.0001
Renal dysfunction (%)
Yes 63.3 29.4 65.6 61.7
No 33.9 54.1 32.4 36.6
Unknown 2.8 16.6 2.0 1.7
P value < 0.0001 < 0.01
Hepatic dysfunction (%)
Yes 23.9 13.0 24.4 23.8
No 66.8 66.7 67.6 68.5
Unknown 9.3 20.3 7.9 7.7
P value < 0.0001 0.71
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therapeutic benefit of DrotAA treatment in IRP A- nega-
tive and IRP B- negative patients.
Neither IRP A nor IRP B predicted ICU and hospital 
survival rates or the destination at hospital discharge. 
At hospital discharge, the mortality rates were 32.2 
and 36.2% for DrotAA group and nonDrotAA groups, 
respectively. Approximately 19% of patients were dis-
charged home, 13% went to long-term care facilities, 
9% went to another acute care hospital, and discharge 
location was unknown for the remainder (24–27%).
Sensitivity analyses with common matching variables 
included as covariates
The inclusion of the common matching variables as 
covariates in the conditional logistic regression model 
did not change any of the conclusions regarding IRP 
A, IRP B, or the overall DrotAA effect (Table  3). We 
used conditional logistic regression and included 
common matching variables (age, APACHE II score 
or SAPS II score, and respiratory dysfunction (yes/
no)) as covariates to correct for residual imbalances 
across IRP genotype subgroups. Neither self-reported 
race nor genetically determined continent of origin 
impacted the overall DrotAA treatment effect or the 
IRP*Treatment interactions in conditional logistic 
regression models.
Sensitivity analyses according to high APACHE II/SAPS II 
scores
As in PROWESS [4] the overall effect of DrotAA differed 
according to severity of illness (Table 4). Greater severity 
of illness was defined by APACHE II ≥25 and by SAPS II 
≥54. ARR based on crude mortality rates was 10.3% in 
the high severity of illness and—1.8% in the low severity 
of illness subgroups.
Sensitivity analyses of individual IRP A and IRP B SNPs
None of the IRP A nor IRP B SNPs was significantly asso-
ciated with treatment effect when analyzed individually.
Secondary endpoints
Time to death in hospital analyses showed a beneficial 
DrotAA treatment effect but no additional benefit to 
knowing IRP A or IRP B genotype (Fig. 2). None of the 
secondary efficacy endpoints analyses (time to death in 
hospital, ICU-free days, hospital-free days, and mechan-
ical-ventilator-free days) showed a significant genotype-
by-treatment interaction (Additional file  1: Supplement 
Tables 22–26).
Discussion
This international, multicenter, retrospective, non-
randomized, controlled, outcome-blinded, genotype-
blinded, and matched-patients study found that neither 
Table 2 Primary efficacy analysis—conditional logistic regression model including AIM Panel PCs
Analysis for IRP A involved 376 discordant matched sets from a total of 637 matched sets
Analysis for IRP B involved 372 discordant matched sets from a total of 634 matched sets
a The interaction odds ratio is a ratio of odds ratios
b A total of 10 AIM Panel PCs were included which accounted for 33.9% of the variance in the AIM Panel data for the Matched-INDICATED Primary Analysis Population 
based on all cohorts
c P values from conditional logistic regression partial likelihood ratio tests for the IRP*Treatment Interaction and the combined AIM Panel PCs; all other P values are 
from Wald Chi-square tests
Factor/effect Estimate SE Odds ratio (OR) estimate OR 95% CI P  valuec
Lower Upper
Primary efficacy analysis for IRP A
IRP A*Treatment  Interactiona − 0.31 0.303 0.731 0.403 1.324 0.30
IRP A+: DrotAA versus NonDrotAA 0.11 0.245 1.112 0.688 1.799 0.66
IRP A−: DrotAA versus NonDrotAA 0.42 0.145 1.522 1.145 2.024 < 0.01
DrotAA: IRP A+ versus IRP A− − 0.30 0.258 0.740 0.446 1.228 0.24
NonDrotAA: IRP A+ versus IRP A− 0.01 0.150 1.013 0.755 1.359 0.93
AIM Panel  PCsb 0.14
Primary efficacy Analysis for IRP B
IRP B*Treatment  Interactiona − 0.09 0.325 0.912 0.482 1.722 0.78
IRP B+: DrotAA versus NonDrotAA 0.23 0.277 1.257 0.730 2.162 0.41
IRP B−: DrotAA versus NonDrotAA 0.32 0.138 1.379 1.052 1.807 0.02
DrotAA: IRP B+ versus IRP B− − 0.19 0.285 0.829 0.475 1.449 0.51
NonDrotAA: IRP B+ versus IRP B− − 0.09 0.156 0.910 0.670 1.236 0.55
AIM Panel  PCsb 0.14
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IRP A nor IRP B predicted differential DrotAA treat-
ment effects on in-hospital mortality through Day 28 in 
patients with severe sepsis. Furthermore, there was no 
significant genotype by treatment interaction for any of 
the secondary endpoints. Nonetheless, as yet undiscov-
ered, other genotypes might accurately predict response 
to DrotAA.
Despite the negative results of the genotype by DrotAA 
treatment interaction, we suggest that this study pro-
vided a potential design for future evaluations of phar-
macogenomic biomarkers of drugs and devices for use 
in sepsis. Most recent and ongoing sepsis trials include 
DNA biobanking. We propose that these trials system-
atically explore potential experimental treatment interac-
tion with genomic biomarkers. If any positive interaction, 
a confirmatory RCT with biomarker-based stratification 
of randomization would then be conducted.
The possible explanations for the negative findings are 
that the prior discovery studies were false positive results 
that did not validate because the biology assumptions 
were incorrect for the biology SNPs and that the statis-
tics were misleading for the statistically chosen SNPs. 
The lessons to be learned for future biomarker trials 
include need for greater validation in prior studies before 
the pivotal trials are done, perhaps focus only on statis-
tically chosen SNPs, and access to prior trials in which 
SNPs were assessed (such as PROWESS in the current 
example).
We believe that this is the largest study of predictive 
genomic biomarkers for any drug used in sepsis. DrotAA 
Table 3 Secondary analysis with  common matching variables included as  covariates—conditional logistic regression 
for differential treatment effects of IRP A and IRP B on mortality
Analysis for IRP A involved 376 discordant matched sets from a total of 637 matched sets
Analysis for IRP B involved 372 discordant matched sets from a total of 634 matched sets
a The interaction odds ratio is a ratio of odds ratios
b A total of 10 AIM Panel PCs were included which account for 33.9% of the variance in the AIM Panel data for the Matched-INDICATED Primary Analysis Population 
based on all cohorts
c P values from conditional logistic regression partial likelihood ratio tests for the IRP*Treatment Interaction and the combined AIM Panel PCs; all other P values are 
from Wald Chi-square tests
d Sites with APACHE II scores were analyzed with 0’s for SAPS II scores, and vice versa
Factor/effect Estimate SE Odds Ratio (OR) 
estimate
OR 95% CI P  valuec
Lower Upper
Analysis for IRP A
IRP A*Treatment  Interactiona −0.34 0.304 0.710 0.391 1.289 0.26
IRP A+ : DrotAA versus NonDrotAA 0.08 0.246 1.087 0.671 1.761 0.74
IRP A−: DrotAA versus NonDrotAA 0.43 0.146 1.532 1.151 2.039 < 0.01
DrotAA: IRP A+ versus IRP A− −0.32 0.259 0.725 0.436 1.205 0.22
NonDrotAA: IRP A+ versus IRP A− 0.02 0.150 1.022 0.761 1.372 0.89
AIM Panel  PCsb 0.13
Common covariates used in matching 0.74
 Age (per year) −0.02 0.024 0.976 0.930 1.023 0.30
 APACHE II (per point)d 0.05 0.080 1.054 0.901 1.233 0.51
 SAPS II (per point)d 0.01 0.041 1.006 0.929 1.091 0.88
 Respiratory dysfunction (Yes vs. No) 0.86 0.778 2.371 0.515 10.90 0.27
Analysis for IRP B
IRP B*Treatment  Interactiona −0.10 0.325 0.908 0.480 1.719 0.77
IRP B+: DrotAA versus NonDrotAA 0.22 0.278 1.251 0.726 2.155 0.42
IRP B−: DrotAA versus NonDrotAA 0.32 0.138 1.377 1.050 1.806 0.02
DrotAA: IRP B+ vs IRP B− −0.19 0.285 0.826 0.472 1.443 0.50
NonDrotAA: IRP B+ vs IRP B− −0.10 0.157 0.909 0.668 1.236 0.54
AIM panel  PCsb 0.15
Common covariates used in matching 0.75
 Age (per year) −0.02 0.024 0.976 0.931 1.024 0.32
 APACHE II (per point)d 0.04 0.080 1.045 0.894 1.223 0.58
 SAPS II (per point)d −0.00 0.041 0.997 0.919 1.081 0.94
 Respiratory dysfunction (Yes vs. No) 0.12 0.935 1.127 0.180 7.050 0.90
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treatment was associated with similar survival benefit in 
the IRP  +  and IRP- genotype subgroups. Self-reported 
ethnicity, genetically assigned continent of origin, and 
high APACHE II/SAPS II analyses did not show predic-
tive genetic IRP effects in any subgroup. Exploratory 
analyses of the four individual IRP SNPs also did not 
show any predictive biomarker effects. Similarly, neither 
IRP A nor IRP B was predictive of differential DrotAA 
treatment effects on secondary efficacy endpoints. Only 
the IRP B +  genotype was associated with significantly 
longer duration in hospital in DrotAA-treated patients 
compared with the IRP B- genotype.
Strengths of this study were first, identification of a 
well-defined and clinically appropriate patient popula-
tion (on-label as defined by the approved indications for 
DrotAA in both the EU and the USA). Secondly, we mini-
mized patient selection bias by using matching to select 
appropriate patients for the control group to overcome 
the lack of randomization to DrotAA treatment. Dro-
tAA was typically given to younger patients with greater 
severity of disease in clinical practice. Therefore, sim-
ply comparing the mortality rates in all DrotAA-treated 
patients to all nonDrotAA-treated patients in the 10 
cohorts would have been invalid. The considerations in 
designing this study were to use either design-based or 
analysis-based methods to control for characteristics that 
differed at baseline between treatment groups. We chose 
to use a design-based approach of matching to tightly 
control for key measures, so that the control group was 
comparable to the treated group. This also permitted effi-
cient use of resources since only a subsample of all pos-
sible controls would be needed for detailed genotypic 
evaluation. The low use of DrotAA in clinical practice for 
patients with severe sepsis in the included cohorts per-
mitted this matched-patients study to be conducted. If 
the drug had been used most of the time in the eligible 
patients, then it would have been very difficult to match 
appropriate nonDrotAA-treated patients as matched 
controls. The matching process was successful in achiev-
ing well-balanced study groups, and balance between 
the two study groups was achieved across IRP genotype 
subgroups (IRP+, IRP−), thus minimizing confounding 
of any biomarker effects (IRP*treatment interaction) by 
baseline differences.
The third strength of the study was quality of data, 
genotyping, and ancestry-control. Extensively reviewed 
Table 4 Secondary analyses for effects of high APACHE II/SAPS II scores on differential treatment effects of IRP A and IRP 
B on mortality—conditional logistic regression models including AIM panel PCs
Analysis for IRP A involves 376 discordant matched sets from a total of 637 matched sets. Analysis for IRP B involves 372 discordant matched sets from a total of 634 
matched sets
a The interaction odds ratio is a ratio of odds ratios
b A total of 10 AIM Panel PCs have been included which account for 33.9% of the variance in the AIM Panel data for the Matched-INDICATED Primary Analysis 
Population based on all cohorts
c P values are from Wald Chi-square tests; the test of the combined AIM Panel PCs is the sum of the individual Wald Chi-square tests
Factor/effect Estimate SE Odds Ratio (OR) 
estimate
OR 95% CI P  valuec
Lower Upper
Analysis for IRP A
Treatment −0.15 0.258 0.861 0.519 1.427 0.56
IRP A −0.08 0.278 0.926 0.537 1.597 0.78
IRP A by treatment  interactiona −0.01 0.535 0.989 0.347 2.819 0.98
High APACHE II/SAPS II Scores −0.06 0.352 0.940 0.472 1.872 0.86
High APACHE II/SAPS II scores by treatment  interactiona 0.82 0.315 2.273 1.226 4.215 < 0.01
High APACHE II/SAPS II scores by IRP A  Interactiona 0.15 0.329 1.164 0.611 2.218 0.65
IRP A by treatment by high APACHE II/SAPS II Scores −0.42 0.651 0.659 0.184 2.360 0.52
AIM Panel  PCsb < 0.01
Analysis for IRP B
Treatment −0.13 0.251 0.880 0.538 1.438 0.61
IRP B 0.14 0.280 1.153 0.666 1.999 0.61
IRP B by treatment  interactiona −0.09 0.541 0.912 0.316 2.635 0.87
High APACHE II/SAPS II Scores 0.10 0.344 1.100 0.561 2.157 0.78
High APACHE II/SAPS II Scores by  Treatmenta 0.63 0.302 1.869 1.033 3.379 0.04
High APACHE II/SAPS II Scores by IRP B  Interactiona −0.35 0.338 0.704 0.363 1.366 0.30
IRP B by treatment by high APACHE II/SAPS II Scores 0.09 0.677 1.092 0.290 4.118 0.90
AIM Panel  PCsb < 0.01
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phenotypic data from all 10 cohorts were combined in 
a common database. Genotyping of the IRP SNPs was 
conducted using a validated Taqman-based method. A 
panel of ancestry informative markers (AIM panel with 
91 SNPs) was genotyped using a qualified GoldenGate 
genotyping method. Quality criteria were applied to the 
genomic data based on per-sample and per-SNP call 
rates and Hardy–Weinberg equilibrium testing. These 
strengths are confirmed by finding similar results to 
PROWESS in that we were successful in overcoming the 
patient selection bias that can occur in a retrospective, 
nonrandomized study.
DrotAA has been suggested to be beneficial in the most 
severe patients, and especially in those with advanced 
coagulopathy. Coagulation dysfunction was diagnosed 
in only 31.8% of the treated patients, which might partly 
explain the negative results. However, we clarify that we 
chose our inclusion criteria to align with the drug label 
and indicated use of DrotAA. Our overall hypothesis 
was that a genomic marker(s) would identify respond-
ers to DrotAA and that a diagnostic kit could then be 
developed to help clinicians decide whom to treat with 
DrotAA.
The SNP selection and interaction test results of the 
prior studies could have been influenced by the so-called 
winner’s curse. If adequate methods had been taken 
to deal with the winner’s curse, then the sample size 
requirement for adequate power may have increased 
because we would not have over-estimated the assumed 
effect size of the IRP.
Although the present results are negative, it is useful 
to discuss the feasibility of IRP detection (including time 
and cost) and treatment allocation based on the pres-
ence of such IRPs. The genotype can be measured now 
in 40–60 min (Cepheid for example), even in the Emer-
gency or ICU setting, and location(s) a time frame rea-
sonable for IRP detection in sepsis and septic shock. The 
cost would depend upon the technology platform cost, 
the reagent costs, and the clinical value of the test results 
based on studies of cost–benefit of the test versus not 
having the test.
Limitations of our study were that the treatment 
assignment of DrotAA was not blinded nor randomized, 
outcomes were obtained retrospectively from databases, 
and we could not assess safety due to lack of adequate 
data. Examples of some confounders that we could 
not control for are physician and judgement regarding 
Fig. 2 Kaplan–Meier curves showing estimated 28‑day mortality rates of approximately 28% for the DrotAA (Xigris) group and 38% for the nonDro‑
tAA group
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patient prognosis and eligibility for treatment with Dro-
tAA, individual ICU or hospital policies regarding use 
of DrotAA, and other underlying disease that we did not 
capture. We did not specifically select patients that were 
randomized in DrotAA trials because we did not have 
access to the trials of DrotAA that collected DNA such as 
PROWESS [4, 16]. Sepsis is a complex trait, so it is likely 
that future research regarding better patient selection for 
treatment will consider several phenotypic biomarkers 
(not just focusing on genetic diversity) with or without 
genotype assessments.
Why were our IRP A and IRP B genotypes not predic-
tive? It is possible that our method of selection of SNPs 
for IRP A and IRP B was inadequate. We used an under-
powered replication cohort to refine SNPs of interest 
from the PROWESS study and we incorporated both 
SNPs based on pure statistical signal in the replication 
cohort as well as SNPs that were chosen based on both 
strength of signal in the replication cohort as well as bio-
logical plausibility. Our study highlights the importance 
and difficulty of validation of predictive genotype-base 
biomarkers in severe sepsis.
Our finding of a beneficial treatment effect of DrotAA 
in the current study differs from PROWESS SHOCK [6] 
and from the APROCCHS trial [7] (in which there was 
no treatment effect) and may reflect selection bias. Addi-
tionally, our study was not randomized, included an ear-
lier era of patients, and we found higher mortality rates 
than in PROWESS SHOCK.
Conclusions
Neither IRP A nor IRP B predicted a differential DrotAA 
treatment effect in patients with severe sepsis and high 
risk of death.
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